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In Mycobacterium tuberculosis, resistance to ethionamide (ETH) is usually combined with 
isoniazid (INH) resistance due to a number of mutations in genes that are involved in the 
biosynthesis of mycolic acids. ETH resistance in INH susceptible isolates is rare. Ten such 
isolates were identified from patients participating in other studies.  
Genotyping by means of IS6110 was performed to compare the relatedness of these isolates 
to each other. In attempts to identify the molecular basis for the resistance to ETH, the ethA, 
mshA and mshC genes were amplified and the amplicons sequenced using an ABI 3730 DNA 
Analyser. INH and ETH minimum inhibitory concentrations (MICs) were determined alone 
and in combination by means of checkerboard titrations in Middlebrook 7H9 broth, using the 
3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and microplate 
alamarblue assays (MABA) for detection of growth.  
Seven isolates were not related to each other and their INH susceptibility was confirmed. No 
mutations were observed in all the sequenced genes. One out of seven isolates was found to 
be co-resistant to INH nad ETH. The MIC for the remaining isolates was 1µg/ml for ETH. 
MABA revealed a paradoxical susceptibility of the isolates to ETH, where mycobacterial 
growth was observed in ETH concentrations higher than the MIC for the six isolates. For 
combination of the two drugs, MABA revealed an antagonism between INH and ETH, where 
the isolates grew in high ETH concentrations regardless of the concentration of INH.  
The paradoxical effect of ETH and antagonism between ETH and INH in our isolates does 
not result from mutations in ethA, mshA or mshC.  
 





Chapter 1: Introduction 
Since its primary discovery by Robert Koch in the second half of the nineteenth century [1], 
Mycobacterium tuberculosis has evolved into multi-drug resistant (MDR) and extensive drug 
resistant (XDR) strains. In the first half of the twentieth century chemotherapy for 
tuberculosis (TB) was deemed unachievable as a result of the lipid-rich cell wall [2]. This 
changed with the discovery of the first anti-tuberculosis drugs streptomycin [3] and para-
aminosalicylic acid [4]. This was followed by the development of isoniazid [5], pyrazinamide 
[6], rifampicin [7] and ethambutol [8]. Shortly after the introduction of the first anti-
tuberculosis drugs, resistance to those drugs was observed [9]. This led to the need for 
accurate and easy to perform drug susceptibility assays [10].  
 
For several decades, treatment with the combination of isoniazid, rifampicin, pyrazinamde 
and ethambutol allowed for effective tuberculosis control in the clinical setting [11]. 
Although the TB epidemic was not completely under control in most developing countries, 
the prevalence was declining. The Human Immunodeficiency Virus (HIV) epidemic changed 
this picture and the number of new cases of TB spun beyond the point of control [12]. This 
lead to the declaration of TB as a worldwide health emergency by the World Health 
Organization (WHO) in 1993. This was followed by intense efforts to advance TB care and 
control nationally and globally [13].  In spite of the accessibility of effective short-course 
chemotherapy (DOTS) and the Bacilli-Calmette-Guerin (BCG) vaccine, tuberculosis is still 
responsible for more deaths than any other infectious agent [14]. The increase of drug 
resistance in clinical isolates of M. tuberculosis has been a major impediment in fighting the 
incidence and spread of TB, and consequently amplified universal labors to comprehend the 




WHO estimated 8.7 million new TB cases in 2011 worldwide with 1.4 million TB related 
deaths [13]. This is almost 20 years after TB was declared a global health emergency [13]. 
This enduring crisis has resulted from disregard of TB by governments, insufficient access to 
health care and infrastructure, unsatisfactory adherence to medication by patients, reduced 
efficiency of TB management programmes, poverty, increase of populace and resettlement, 
and a major increase in the amount of TB cases in HIV infected persons [11].  
 
MDR-TB is TB caused by bacilli that are resistant to isoniazid (INH) and rifampicin (RIF), 
which are the two most potent first-line drugs used in TB treatment [16]. XDR-TB results 
from bacilli that are resistant to fluoroquinolones, and any one of the injectable second-line 
drugs such as capreomycin, kanamycin or amikacin, on top of the two first-line drugs, 
consequently resulting in an elevated death rate especially in individuals co-infected with 
HIV [17 – 19].  
 
The distinguishing traits of M. tuberculosis comprise dormancy, intricate cell envelope and 
intracellular survival and growth [20], which makes it intrinsically resistant to the action of 
many drugs that kill other pathogenic bacteria. Not many organisms generate such a varied 
range of lipid molecules as M. tuberculosis. These vary from a number of simple fatty acids, 
to very long-chain, extremely composite molecules. These molecules are known as mycolic 
acids [20].  
 
The general understanding of tuberculosis drug resistance has significantly improved through 
the use of molecular techniques [10]. M. tuberculosis uses a number of strategies to oppose 
the action of anti-bacterial drugs [21]. One of these is reduced cell wall permeability, 
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resulting from the highly hydrophobic mycobacterial cell envelope [22, 23]. Genes that are 
linked with active drug efflux systems and degrading inactivating enzymes have been found 
in M. tuberculosis, which also aid in drug resistance [20, 24].  
 
Exogenous agents, DNA polymerase errors, deletions, insertions and duplications are 
common means of mediating mutations in any prokaryotic genome through regular base 
changes, and these result in drug resistance in many prokaryotes [11]. This includes 
resistance of M. tuberculosis to anti-TB agents. Resistance to anti-TB drugs has been 
previously shown to be predominantly the effect of innate mutations in genes encoding drug 
targets, or enzymes implicated in drug activation [21]. Such mechanisms of resistance have 
been identified for all first-line and for various second-line drugs, including ethionamide [25 
– 28].  
 
ETH monoresitance in clinical isolates is rare. In this study, eleven M. tuberculosis clinical 
isolates were identified which, based on breakpoint testing, are phenotypically resistant to 
ETH, while showing full susceptibility to INH. To ensure that these isolates were not the 
same strain, these isolates were genotyped by means of IS6110 fingerprinting to compare 
their relatedness to each other. In an attempt to determine the molecular basis for ETH 
resistance in these isolates, ethA, mshA and mshC genes were sequenced, which are 
commonly implicated in high level resistance to ETH [33 – 35]. Finally, cell viability 
detection assays were performed to determine the precise minimum inhibitory concentrations 




Chapter 2: Isoniazid and Ethionamide 
2.1 Isoniazid  
Before the discovery of isoniazid (INH), the treatment of TB was not very effective, as it was 
restricted to a few antimicrobial agents and synthetic drugs [29]. Broad-spectrum 
antimicrobial agents were not effective against TB [29]. The process leading to the discovery 
of isoniazid in 1952 began with the finding in the mid 1940s, by researchers in Europe, that 
nicotinamide was effective against TB [36]. Pyrazinamide was discovered as a result of the 
production of new synthetic molecules based on nicotinamide [37]. However, M. tuberculosis 
rapidly became resistant to pyrazinamide [37], hence the continued search for more effective 
antituberculosis agents. The β- and γ-pyridylaldehyde thiosemicarbazones, which 
demonstrated better activity against the tubercle bacilli, were synthesized in an effort to 
improve the activity of nicotinamide and other related compounds [29]. A breakthrough was 
achieved when one of the intermediates in the production of γ-pyridylaldehyde 
thiosemicarbazone , isonicotinic acid hydrazide (INH) had an unexpected increased effect 
against TB [38; 39], significantly higher than other antimicrobial agents used at the time [38; 
39]. INH is still one of the main drugs used in TB chemotherapy [29]. 
 
2.2 Ethionamide  
Ethionamide (2-ethylthioisonicotinamide, ETH) was first discovered in 1956 [40]; like 
isoniazid, ETH is a prodrug which requires metabolic activation [32] by the mycobacterial 
monooxygenase EthA [41]. It has been previously shown that ETH has a strong bacteriostatic 
effect against mycobacteria, more especially against isoniazid resistant mutants [33]. 
Resistance of mycobacterial strains to ethionamide is often coupled with resistance to 
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isoniazid, although there have been cases where resistance to isoniazid in mycobacteria has 
been observed with no co-resistance to ethionamide [42 – 43]. Treatment of MDR-TB still 
greatly relies on the use of the second line drug ETH [44]. ETH is a narrow-spectrum 
molecule, and like many other drugs used in the treatment of tuberculosis, the activity of 
ETH is mostly limited to mycobacteria, most likely as a result of the specificity of its 
interaction with essential components unique to mycobacteria [45]. On the other hand, the 
specificity may be due to the buildup or activation of ETH by uptake systems or converting 
enzymes only found in mycobacteria [45]. As a result of its high toxicity levels, the use of 
ETH in the treatment of infections caused by agents in the mycobacteria family is limited 
[46].  
 
2.3 Inhibition of Mycolic Acids 
INH and ETH are generally active against mycobacterial bacilli [29] by inhibiting mycolic 
acid biosynthesis [47]. Mycolic acids are long-chain α-alkyl-β-hydroxy fatty acids [29], and 
these substances are uniquely found in mycobacteria and related genera [48]. Mycolic acids 
play a critical function in mycobacterial-envelope structural design, forming an intersection 
between the capsule and the cell-wall frame, where they are covalently bound [49]. Winder & 
Collin in 1970 first demonstrated the inhibition of mycolic acids by INH, where they 
observed an inhibition of mycolic acid synthesis in M. tuberculosis H37Ra and M. bovis BCG 
following treatment with INH; similar inhibition patterns were not observed in INH resistant 
strains [47]. Two years later, Takayama and colleagues confirmed the inhibition of mycolic 
acid synthesis in M. tuberculosis treated with INH [50]; further, they demonstrated that this 
inhibition was linked to cell death [50] as well as the accretion of long chain fatty acids [51]. 
Previous research shows that INH treatment results in major damage to the envelope 
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organization, such as loss of the acid-fastness [52], discharge of irregular quantities of 
proteins into the culture medium and distorted ultrastructure [53].  
 
2.4 Mechanism of Action of Isoniazid 
INH is a pro-drug which requires activation by the mycobacterial enzyme catalase-peroxidase 
(KatG) [54] in combination with NADH oxidase [55]. NADPH oxidase-derived peroxidase 
activity of KatG seems essential in activation of INH [56]. Treatment with INH induces a 
powerful selection for INH-resistant mutants, where most mutations are found in the katG 
gene [54; 55; 58]. KatG activates INH, in concurrence with its peroxidase activity, by 
peroxidation to generate intracellular, reactive, INH-derived toxic species [59]. A variety of 
oxidants support KatG oxidation of INH, including superoxide [60], hydrogen peroxide [61] 
and simple alkyl hydroperoxides [62]. The in vitro auto-oxidation of INH [63] and NADH, 
when utilised [61], can supply adequate oxidants to permit INH activation by KatG, even if 
there is a deficiency of supplementary oxidants [63]. It is possible that the oxidant in vivo is a 
low flux of hydrogen peroxide that may occur inside the bacteria as a by-product of aerobic 
metabolism [61]. Both these superoxide- and low-flux hydrogen peroxide-oxidizing systems 
demonstrate the anticipated decline in the capacity of mutant S315T KatG to activate INH in 
vitro, in comparison to alkyl hydroperoxides which do not [63],  however, of these the in 
vitro oxidant species has not been established [59]. Horseradish peroxidase [64; 65] or even 
inorganic manganese ions [66; 67] have been previously postulated to be possible model-
oxidising systems which may be capable of activating INH. Nevertheless, it has not been 
decided if these representation oxidants precisely imitate the accurate species produced by 
KatG, since even greatly associated KatG enzymes can vary in the products they generate 
[68]. The crystal structures of KatG [69; 70] and recently the S315T variant [61] give an 
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improved understanding of the mechanisms by which INH is activated. The contraction of the 
haem access channel from 6 Å ´ in the wild type to 4.7 Å ´ in the S315T variant implies that 
diminished INH access to the oxidizing site of KatG may be the means to resistance, this is in 
agreement with prior spectroscopic analyses [71 – 73]. In the NAD+ or NADP+ deficiency, 
no considerable constant anti-tubercular products resulting from INH metabolism are 
generated during in vitro activation [59]. Consequently, reactive intermediates resulting from 
INH metabolism are essential to the efficacy of INH [59]. KatG oxidatively activates INH 
through the formation of a variety of carbon-, oxygen- and nitrogen-centered free radical 
species, with the formation of acyl, acylperoxo and pyridyl radical adducts of 
phenylbutylnitrone (PBN) projected from outcomes of spin trapping experiments [63]. 
Nevertheless, the differentiation of dissimilar adducts of PBN by hyperfine coupling constant 
alone is convoluted, thus these allocations remain rather uncertain [74]. The spin trap 5,5- 
dimethyl-1-pyrolline-N-oxide (DMPO) frequently permits improved allocations than PBN,  
since the variety of hyperfine coupling constants of its spin adducts are wider [59]. 
Consequently, species formed from INH allocated as carbon-centred and alkoxyl adducts of 
DMPO have been observed upon KatG oxidation of INH [75], with an extra peroxyl radical 
species observed in the presence of molecular oxygen, due to a reaction of one of these 
radicals with O2 [59]. The nitric oxide radical (NO·) has also been trapped from KatG 
oxidation of INH, with 15N isotopic labelling of INH hydrazide resulting in 15NO· [75; 76]. 
The outcomes of other oxidizing systems imply that the hydrazyl radical [77] can be easily 
formed by INH oxidation and is possibly a preliminary product, although verification with a 
proper KatG enzyme is necessary [59]. In spite of these advances, the necessity to describe 
the nature of these radical intermediates remains, and in particular, to show ultimately the 
formation of the isonicotinoyl radical [78], since this is the crucial intermediate that adds to 
NAD+ and NADP+ to generate a variety of potent inhibitors [59]. While it took long to 
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establish the mechanisms, it had been known for ages that INH disturbs production of both 
mycolic acids [47; 50] and nucleic acids [80]. The discovery that oxidation of INH in the 
presence of NADH and InhA led to covalent INH-NADH adducts that are potent inhibitors of 
InhA [80] was a major advance [59]. InhA mediates the production of mycolic acids [81], 
which are exclusive and essential mycobacterial cell wall lipids, and so its inhibition is in 
harmony with the characteristic susceptibility of mycobacteria to INH [59]. The metabolic 
effects of NADH/NAD+ ratios on INH susceptibility in mycobacteria supports the function 
of NAD+ in production of INH-NAD adducts [82], in which decreased NAD+ levels caused 
INH resistance, and also by mutations in the NADH oxidase gene ndh in some isolates 
resistant to INH [83]. INH-NAD adducts proficient in InhA inhibition are formed both in 
simple Mn/INH/NADH mixtures [66; 78; 84] and in KatG-mediated reactions. The S isomer 
binds to InhA when the stereochemical centre is produced by the addition of the isonicotinoyl 
radical to NAD+ in the INH-NAD adduct [80]. This S isomer is generated as a tight-binding 
(Ki = 0.75 nM) inhibitor [85]. The two primary INH-NAD adducts generates a variety of 
diastereoisomers upon subsequent cyclization [66; 67; 84]; however, these do not seem to 
have the inhibitory effect which the acyclic S isomer has on InhA [59]. The coupling of 
activated INH with NADP+ may possibly occur, in vitro these INH-NADP adducts are a 
potent inhibitor of MabA, an NADPH dependent b-ketoacyl-ACP reductase which is also 
vital in the synthesis of mycolic acids [86]. Consequently, INH adducts of both NAD+ and 
NADP+ may well inhibit various steps in cell wall lipid synthesis, though an in vivo role for 
MabA inhibition has not been demonstrated yet [59]. Additionally, previous studies have 
revealed that the acyclic 4R isomer of the INH-NADP adduct binds M. tuberculosis 
dihydrofolate reductase (DHFR), which is essential in nucleic acid biosynthesis to generate 
nucleotide pools, with a Ki less than 1 nM [87]. Even though it seemed as if an INH adduct of 
KasA, another mycolic acid synthetic enzyme, may arise by means of an INH-induced 80 
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kDa covalent complex consisting of KasA, AcpM and an INH-derived isonicotinic acyl 
fragment [88], it appears probable that effects on KasA are mediated through INH-NAD 
adduct inhibition of InhA [89] as an outcome of its identified close regulation with InhA [90]. 
The comparative importance of InhA and KasA as targets has been further elucidated by 
inducing mutations seen in clinical isolates, such as the S94A mutation found on the inhA 
gene in wild-type mycobacteria [91]. The induced S94A mutation amplified INH resistance, 
whereas kasA mutants G269S as well as F413L were unable to produce a similar effect [91]. 
Accordingly, a variety of strong INH-NAD/NADP inhibitors have been described, and in 
general, the essential genetic alterations of target mycobacteria have resulted in the expected 
alteration in INH sensitivity [59]. Nonetheless, an increased concentration of NAD+/NADP+ 
and a very low concentration of other molecules with the ability to react with the isonicotinic 
acyl radical was used in these in vitro systems , in so doing compelling the isonicotinoyl 
radical to react with NAD+ or NADP+ [59]. The isonicotinoyl radical will be highly reactive 
with a broad variety of reactants as for other acyl radicals [92; 93] such as proteins, 
mycothiol and unsaturated lipids [94]. Thus, when generated within the tubercle bacilli, the 
isonicotinoyl radical will react mostly with other molecules rather than NAD+ or NADP+, 
that are present at only ~0.4 mM and 0.2 mM, respectively, in M. tuberculosis [79]. While the 
gathered data is persuasive, final verification of the function of these INH-NAD and INH-
NADP species will necessitate their isolation from INH-treated mycobacteria at 
concentrations concurring with a considerable inhibitory effect from their known Kis [59]. 
 
2.5 Mechanism of action of ethionamide 
The mode of action of ETH upon activation is through the inhibition of the enoyl-ACP 
reductase [30; 95] enzyme which is encoded by the inhA gene and forms part of the mycolic 
acid biosynthesis system [96]. The activation of ETH is via the ethA gene encoded mono-
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oxygenase (EthA), which results in the formation of an S-oxide metabolite (ETH-SO) [33; 
97], possibly a sulfinate, which demonstrates superior bactericidal action against M. 
tuberculosis compared to the inactivated form of ETH in vitro [33]. Previous studies have 
implied that ETH-SO maintains the biological activity of the inactivated form of the drug 
[98] which correlates with the fact that a number of drugs used in TB treatment, including 
ETH, need some kind of metabollic activation parallel to the oxidative, reductive, or 
hydrolytic unmasking of active groups [99 – 101].   
 
2.6 Killing by isoniazid  
Passive diffusion is the mode of entry of INH into the mycobacterial cell interior [102] which 
then kills only dividing bacteria; no killing of mycobacterial cells is seen during stationary 
phase or when the bacteria are growing under anaerobic conditions [103]. During the first 24 
hours of INH administration, the action of INH against M. tuberculosis is bacteriostatic, 
followed by the killing of the bacteria [29]. It has also been reported in the past that there is a 
postponement from 1 to 4 days before INH begins its bacteriocidal action [52; 103 – 105]; in 
the meanwhile, the mycobacterial cells lose their acid fastness [52; 105]. INH also brings 
about physical alterations in mycobacterial cells, such as the loss of inner structure and the 
emergence of surface wrinkles and bulging [106 – 108].  
 
2.7 Genes associated with ETH resistance 
In the year 2000, Baulard et al and DeBarber et al separately identified the EthA and EthR 
genes which are implicated in the activation of ETH [33; 34]. EthA is a FAD-containing 
enzyme that mediates two steps in the activation of ETH [41]. The resistance of M. 
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tuberculosis to ETH has been ascribed to the transcriptional suppression of ethA applied by 
the bacterial regulator EthR, encoded by the ethA neighboring gene ethR [45]. EthR was 
shown to repress the expression of ethA, the binding of EthR upstream of ethA results in the 
suppression of ethA expression [45]. In wild-type mycobacteria, some of the ETH molecules 
remain unactivated [45]. This has been signified by the linking of the chromosomal 
inactivation of ethR with ETH hypersensitivity, and as a result, EthR adds to the resistance of 
M. tuberculosis to ETH [96]. EthR was proposed and confirmed as a drug target to boost the 
bioactivation of ethionamide and increase the efficacy of ETH in vivo [109]. Flipo and 
colleagues observed and documented structure−activity relationships of a progression of 
druglike 1,2,4-oxadiazole EthR inhibitors identified via a judicious drug design approach 
[110; 111]. In 2008, Vilcheze et al showed that mutations in the glycosytranferase MshA 
encoding gene, mshA, resulted in high level resistance of spontaneous mutants of M. 
tuberculosis [35]. MshA mediates the first step in mycothiol biosynthesis [112; 113], which 
had been previously reported to be crucial in the survival of M. tuberculosis [114]. However, 
Vilcheze and colleagues showed that some M. tuberculosis mutants deficient of mycothiol 
were viable [35]. Most mutations in genes that mediate mycothiol biosynthesis were found to 
confer ETH and INH resistance. Vilcheze and colleagues later showed that in vitro induced 
mshA and mshC mutations were responsible for high level resistance to ETH and low level 
resistance to INH [99]. Mutations in the mshA gene, however, must be carefully examined 
because some clinical isolates showing phenotypic susceptibility to ETH and INH have been 






2.8 Common INH Resistance Conferring Mutations  
Mutations in katG, a gene encoding the INH activator, are the most common cause of INH 
resistance in M. tuberculosis. This results in a decline in or loss of catalase-peroxidase 
activity [57; 115; 116]. There have been observed insertions, deletions, truncation, missense 
and nonsense mutations, and less frequently, full gene deletion [55; 117; 118]. S315T 
mutation, which harbours a product which has a highly decreased capacity to form the INH-
NAD adduct, is most common in katG [116 – 122]. Consequently, M. tuberculosis strains 
with a mutation in katG are most probably resistant to INH as a result of a lowered capacity 
to form the INH-NAD adduct, which is the InhA inhibitor. The subsequent mutation detected 
in an INH resistant strain was the mutation in inhA [32] which ecodes the enzyme enoyl-acyl 
carrier protein reductase (InhA). This mutation decreases the attraction of InhA for its 
cofactor NADH and is located in the NADH binding pocket of InhA [32]. Consequently, the 
InhA (S94A) protein has a greater Ki for the INH-NAD adduct and is more resistant to the 
inhibition by the INH-NAD adduct than the wild-type enzyme [91]. This mutation disrupts 
the hydrogen bonding network, as indicated by X-ray crystallographic structural 
determinations [91]. Consequently, an INH-NAD adduct with reduced binding abilities to 
InhA is formed [91]. Other INH resistance conferring mutations in inhA, such as I16T, I21V, 
I47T, and I95P, are also situated in the NADH binding pocket and diminish the affinity for 
NADH [124]. When a M. tuberculosis isolate is resistant to INH, mutations in the inhA gene 
are not always found but if they are found, these typically coexist with mutations in the 
promoter region of katG or inhA mutations [116 – 119; 121 – 124]. Overexpression of inhA 
is another way in which M. tuberculosis can become resistant to INH. This resistance results 
from dilution of INH by the InhA enzyme [29]. The C-15T inhA promoter mutation is the 
second most frequent mutation in INH-resistant M. tuberculosis clinical isolates [116 – 122]. 
This mutation results in InhA overexpression by increasing the inhA mRNA level 20 times as 
21	  
	  
compared to the wild-type, resulting in a much higher resistance of mycobacteria to INH 
[91]. Mutations in the NADH dehydrogenase NdhII were initially found in INH-resistant M. 
smegmatis laboratory strains [82]. INH-resistant M. bovis BCG laboratory strains were later 
shown to also harbour ndh mutations [99]. The ndh mutants had low NdhII activity, which 
resulted in an accrual of NADH, the substrate for NdhII [99]. This NADH accumulation 
played the role of a competitive inhibitor for binding to InhA and shielded InhA from the 
inhibitory effect of the INH-NAD adduct [99]. R268H is the only mutation in ndh that has 
been reported to occur in clinical isolates of INH-resistant M. tuberculosis [122; 125]. The 
inactivation of INH by the nat-encoded arylamine N-acetyltransferase (Nat) is another means 
of resistance [29]. The acetylation of the nitrogen group of INH by M. tuberculosis Nat 
prevents the activation of INH by KatG [126; 127]. Following transformation with the 
mycobacterial expression vector pACE-1, overexpression of M. tuberculosis nat results in an 
increased level of INH tolerance in M. smegmatis [126]. However, mutations in nat identified 
in clinical isolates of INH resistant M. tuberculosis were constantly interrelated with katG 
mutations and also observed in INH-sensitive clinical isolates [116]. 
 
2.9 Other Mutations Conferring INH Resistance 
INH resistance has also been observed in M. smegmatis strains lacking in mycothiol [29].  
The genes, mshA, mshB, mshC, and mshD, mediate the biosynthesis of mycothiol with M. 
smegmatis mutants having a transposon in either mshA [129], mshC [129], or mshD [130]. 
This renders the organisms extremely resistant to INH [29]. A M. smegmatis mshB mutant 
was surprisingly found to be sensitive to INH [131], while a twofold increase in INH 
resistance was seen in a M. tuberculosis mshB mutant [131]. The reasons for INH-resistance 
in mycothiol deficient mutants are not yet understood although it has been hypothesized that 
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mycothiol is necessary for the activation of INH [129; 131]. Other mutations found to 
facilitate INH resistance in clinical strains of M. tuberculosis include mutations found in 
furA, afpC, fadE24 and kasA [116; 117; 120; 122; 132 – 137]. However, these mutations 
were often related to katG and/or inhA mutations in promoter region, or were also present in 
INH-susceptible clinical isolates [29].  
 
2.10 INH Tolerance Conferring Mutations 
Almost all of the M. tuberculosis cells die within 3 to 4 days after treatment with INH [29]. 
The surviving tubercle bacilli signifies a heterogeneous population made up of bacilli that 
have either acquired their INH resistance through spontaneous mutations or are genetically 
sensitive to INH but maintaining tolerance to the drug [29]. This drug tolerance phenotype 
was characterized by testing the INH-inducible iniBAC operon, which encodes an 
unidentified membrane transporter, for its capability to shield M. tuberculosis against cell 
wall synthesis inhibitors like INH and ethambutol [138]. This research led to the finding that 
the iniA gene in M. tuberculosis, upon overexpression, conferred a multidrug-tolerant 
phenotype to both INH and ethambutol [138]. However, Colangeli and co-workers [138] 
showed that the IniA protein on its own does not work as a drug transporter and hypothesized 







Chapter 3: Methodology 
Ethical clearance to conduct this study was obtained from the University of KwaZulu Natal 
Biomedical Research Ethics Committee (BREC), reference number BE067/12. 
 
3.1 Bacterial strains and media 
 Mycobacterium tuberculosis clinical isolates from patients admitted to the Church of 
Scotland Hospital in Tugella Ferry in 2007 were obtained from storage. The susceptibility of 
these isolates was identified using the agar incorporation method on Middlebrook 7H10 agar 
(Difco, Becton and Dickenson, USA). The concentrations used were 1 mg/L for isoniazid 
(INH) (Sigma-Aldrich (Pty) LTD, SA) and 2.5 mg/L for ethionamide (ETH) (Sigma-Aldrich 
(Pty) LTD, SA). Susceptibility was defined as the absence of growth and resistance was 
defined as growth of any number of colonies. The isolates were grown in Middlebrook 7H9  
liquid medium (Difco, Becton and Dickenson, USA) supplemented with 10% (v/v) OADC 
(BD, USA) enrichment (Difco) and 0.2% (v/v) glycerol.  
DNA was extracted from these isolates to perform IS1660 fingerprinting as well as 
sequencing of predefined genes. Quantitative susceptibility to isoniazid and ethionamide 
alone and in combination was also performed. 
 
3.2 DNA Extraction  
Once an OD600nm of 1 has been reached, 2 ml of the culture was transferred into an Eppendorf 
tube (Merck, USA) and centrifuged for 10 min at 3000 x g. The supernatant was discarded 
and the deposit was resuspended in 500 µl triple distilled water and killed by exposure to 
80ºC for 30 min. This was followed by the addition of 70 µl of 10% sodium dodecyl sulphate 
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(SDS) (Sigma-Aldrich (Pty) LTD, SA) and 50 µl proteinase K (10 mg/ml) (Roche, SA) and 
incubation at 60ºC for 1 hour. A solution of 5M NaCl and CTAB (10% CTAB, 0.7M NaCl) 
was pre-heated to 60ºC and 100 µl 5M NaCl was added. The tube’s contents were mixed by 
inverting repeatedly. The mixtures were incubated at 60ºC for 15 min then frozen at -70ºC for 
another 15 min. The tubes were removed and defrosted at 60ºC, 700 µl chloroform-isoamyl 
alcohol (24:1) was added and the contents were mixed by inversion by hand 20-25 times 
followed by centrifugation at 13000 x g for 10 min. The upper aqueous phase was transferred 
to a tube with 700 µl cold isopropanol and mixed by tilting the tubes up and down several 
times. These mixtures were incubated at -20ºC for 30 min. The tubes were centrifuged for 10 
min at room temperature (25⁰C). The supernatants were drained and the pellets were washed 
with 80% ethanol and centrifuged for 5-10 min. The liquid was drained and the pellets were 
dried in speed vacuum for about 5 minutes. Following this 55 µl 1x TE was added. The DNA 
quality was checked by electrophoresis in a 1% agarose gel.  
 
3.3 Gel Electrophoresis 
Seakem agarose gel powder (Whitehead Scientific, SA) was dissolved in 1X TBE buffer (0.3 
g in 30 ml) by heating in a microwave oven for 30 sec. Ethidium bromide (Sigma-Aldrich 
(Pty) LTD, SA) was added to a final concentration of 0.5 mg/L. The mixture was poured onto 
a Hoefer gel electrophoresis tray (7 cm X 10 cm) and was left to solidify at room temperature 
(25⁰C). The gel was placed on a Hoefer electrophoresis machine containing 1XTBE buffer. 
Each well was loaded with 1 µl DNA mixed with 5 µl of gel loading buffer. The gel was run 
for 30 min at 100 V and then viewed under UV light to check the quality and the approximate 




3.4 IS6110 Restriction Fragment Length Polymorphisms (RFLPs)  
 
Endonuclease restriction 
Similar amount of DNA of each isolate were diluted with distilled water to reach a final 
volume of 22 µl. This was mixed with 2.5 µl PvuII buffer, and 1.5 µl of 5000 U PvuII 
enzyme and incubated for three and half hours in a water bath at 37⁰C. The digested samples 
were run in a 1% agarose gel (15 cm X 20 cm) for 30 min at 90  V and then overnight at 36 V 
on a Hoefer electrophoresis machine. 
 
Southern blot 
A Hybond-N+ membrane (Amersham-GE Health, USA) was briefly submerged in water and 
then soaked in 10X SSC (Annexure 4) for 5 min. The gel was placed on the prepared 
membrane. A vacuum of -55 cm mbar was created by means of a GE-Health Vacugen-XL 
vacuum pump. The gel was flooded with 1/100 HCl for 20 min after which the liquid was 
removed. The gel was flooded with Soak I (Annexure 4) for 20 min and, after removal of the 
fluid, again with Soak II for 20 min. The gel was once more submerged in 10X SSC for 1.5 
hours after which the fluids were removed by vacuum. After removal of the gel, the 
membrane was allowed to dry for 5 min. To optimize the cross links, the membrane was 
briefly irradiated under UV (UVP-CL1000). 
 
Hybridization  
The probes used were manufactured by PCR (Annexure 3) according to van Embden et al 
(1993). The membrane was emersed in 20 ml of hybridization buffer while rotating at ~5 
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RPM at 42ºC for 30 min. A mixture of equal volumes of 10 µl of probe and 10 µl of water 
was boiled for 5 min and then placed on ice for 10 min. To this, 20 µl of labeling agent and 
20 µl of glutaraldehyde (Amersham ECL Direct Nucleic Acid Labeling and Detection 
System – RPN 3000) were added followed by incubation in a 37ºC water bath for 15 min. 
The probe was added to the hybridization buffer at the required concentration. Hybridization 
was allowed overnight in a rotating incubator at 6 RPM at 42ºC. 
 
Detection of banding pattern 
Following hybridisation, the membrane was briefly rinsed with primary wash buffer. The 
tube containing the membrane in fresh primary wash buffer was rotated for 30 min at ~5 
RPM at 42ºC. The membrane was removed from the tube and soaked in secondary wash 
buffer on a Stuart Orbital SSL1 shaking platform for 10 min. The liquid was discarded and 
the above step was repeated. 
The membrane was incubated (1 min at + 25oC) in a mixture of 5 ml of Soak I and 5 ml of 
Soak II, wrapped in plastic and placed with the Amersham Hyperfilm ECL in a cassette 
(Amersham, USA) and developed by chemiluminescence in a dark room till bands with the 
required density were observed.  
 
3.5 Minimum Inhibitory Concentrations (MICs)  
Minimum inhibitory concentrations (MIC) to INH and ETH were determined for the M. 
tuberculosis isolates using the 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) (Include ref) and the microplate alamar blue assays (MABA) (ref: fransblau, ref# 
141). Cultures were incubated till the log phase of growth was reached, indicated by an 
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OD600nm of 1. This corresponds with a growth density of 108 cfu/mL. A test inoculum of 103 
cfu/mL for each isolate was prepared by serially diluting the cultures in Middlebrook 7H9 
broth. Stock solutions of INH and ETH were prepared in distilled water and dimethyl 
sulfoxide (DMSO) respectively. Both solutions were filter sterilized. Serial 2-fold dilutions 
were made in the wells of a microtiterplate with 7H9 broth as diluent. To each test well, 
containing 50 µl of drug solution, 50 µl of the test inoculum was added. The final 
concentrations for INH were 16, 8, 4, 2, 1, 0.5 and 0.25 µg/ml and for ETH 64, 32, 16, 8, 4, 2 
and 1 µg/ml. The plates were incubated for seven days in a 37ºC O2 incubator before the 
respective colorimetric reagents were added. Both the MTT assay and MABA was done in 
triplicate to test for intra-test variation and both were repeated in triplicate on different days 
to test for inter-test variation.  
 
The MTT solution was prepared by dissolving 0.00513 g MTT powder (Sigma-Aldrich (Pty) 
LTD, SA) in 1 ml 7H9 broth and filter sterilized. Of the MTT solution 7.5 µl was added to 
each well of the MIC microtiter plate. After a further incubation period of 24 hours, 25 µl of 
20% sodium dodecyl sulphate (SDS) solution with N1N-dimethylformamide (DMF) (Sigma-
Aldrich (Pty) LTD, SA)  [1:1 vol/vol] was added to each well. This was followed by an 
additional 24 hour incubation step to allow for colour development. A purple colour and/or 
precipitate indicates bacterial growth. 
 
For the MABA, at the end of the 7-day incubation period of the MIC microtiterplates, 15 µl 
of AlamarBlue® reagent (Life Technologies, SA) was added to each well. The plates were 
further incubated for 24 hours. A colour change from blue to pink indicates bacterial growth. 




 3.6 Checkerboard Titrations 
Plates for the checkerboard titrations were prepared as shown in (figure 3.6.1).  
	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	  
A	   E64   I16   18   I4   I2   I1   I0.5   I0.25   I0.125   I0.062
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Figure 3.6.1: Representation of checkerboard titration assays.  
E = ethionamide; I = isoniazid; numerical values = drug concentrations. 
 
3.7 DNA sequencing and analysis 
The extracted DNA samples were shipped to Jacobs Lab at the Albert Einstein College of 
Medicine (New York) where PCR amplification of the mshA, mshC and ethA genes was 
performed followed by amplicon sequencing and analysis of the data obtained. 
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Polymerase Chain Reaction (PCR) Amplification 







A PCR kit from Applied Biosystems (Life Technologies, USA) was used. The composition 
of the master mix is shown in table 3.7.1. Of this master mix, 49 µl volumes were aliquoted 
into PCR tubes and 1 µl of extracted DNA was added. The PCR final reagent concentrations 
and cycling steps are summarized in table 3.7.1 and table 3.7.2 respectively. 
 
Table 3.7.1 Final concentrations of the PCR components  
Master Mix component for a 100 µl reaction Concentration  
dNTPs 40 nmol 
PCR Buffer II, 10X 10 µl  
MgCl2 300 nM 
Reverse primer 40 pmol 
Forward primer 40 pmol 













Temperature (ºC)    94       94     55    72    72  
Duration (min)    5     30 sec     1   1.30    7 
Number of PCR cycles: 40 
 
Purification of PCR products 
To each PCR product, 250 µl of buffer PB provided with the QIAquick PCR purification kit 
was added in a QIAquick spin column. The mixture was centrifuged for 60 sec. The flow-
through was discarded and 0.75 ml of buffer PE was added to the column and centrifuged for 
an additional 60 sec. The column was placed in a clean 1.5 ml microcentrifuge tube. To elute 
the DNA, 30 µl of elution buffer was added to the centre of the QIAqiuck membrane of the 
column. The column was allowed to stand for 2 min and then centrifuged for 2 min.  
 
DNA Sequencing 
DNA sequencing was performed at the Albert Einstein College of Medicine DNA sequencing 
facility using an ABI 3730 DNA Analyzer. To prepare the sample, 3.2 µl of each primer was 
aliquoted in separate tubes and 2 µl of purified PCR product was added to each tube. The 
samples were sent to the sequencing facility for DNA sequencing. The sequences were 




Chapter 4: Results  
4.1 Restriction Fragment Length Polymorphism Genotyping 
The result of the DNA extraction of all 10 isoniazid susceptible but ethionamide resistant 
Mycobacterium tuberculosis isolates was checked by means of elecrophoresis. The results are 
shown in Fig. 4.1.1 One isolate (TF2232, lane 9) was resistant to both drugs.  
 
Figure 4.1.1: DNA gel image of INH susceptible ETH resistant isolates of M. tuberculosis. 1: 
marker 2, 2: TF727, 3: TF1701, 4: TF1719, 5: TF1734, 6: TF2205, 7: TF2204, 8: TF2226, 9: 
TF2232, 10: TF1400, 11: TF1735 and 12: TF1091.  
 
Seven out of ten isolates had distinct restriction patterns. Four isolates (TF1701, TF1719, 
TF1734 and TF1735) showed identical restriction patterns. Therefore only one (TF1719) of 




Figure 4.1.2: IS6110 RFLP dendogram showing restriction patterns of M. tuberculosis 
isolates.  The TF isolate numbers are shown on the right side of the dendogram. 
 
4.2 Checkerboard Titrations 
 4.2.1 Tetrazolium Microplate Assay 
The results of the checkerboard titration using 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) microplate assay is shown in figure 4.2.1.1. The lay-out of the 
plate is as shown in figure 3.6.1. As mentioned in chapter 3.5 bacteria were exposed to the 
drugs for 7 days followed by overnight incubation with the reagent. The MIC for INH was 
>.0.0625 mg/L (A2 – A10) and 2 mg/L for ETH. However, the MTT reagent also showed a 
reaction with the 4 to 5 highest ETH concentrations (A1-D1/E1). 


































































The assay was repeated without bacteria. After 7 days of incubation a colour change was 
observed in all wells, independent of the ETH concentration (not shown). Therefore, the 
microplate alamar blue assay (MABA) was employed for the detection of bacterial growth. 
  
Figure 4.2.1.1: Checkerboard MTT assay 
Blue-black: bacterial growth,  
Row 11: positive control  
Row 12 negative control. 
 
          4.2.2 Microplate Alamar Blue Assay 
The results of the checkerboard titration of INH and ETH using the Microplate Alamar Blue 
Assay (MABA) as shown in figure 4.2.2.1. The lay-out of the plate is as shown in 3.6.1. No 





Figure 4.2.2.1: Checkerboard titration with Microplate Alamar Blue Assay  
Pink= bacterial growth, 
Row 11: positive control  
Row 12 negative control  
 
With INH only (wells A2 – A10), growth inhibition was observed in all wells, resulting in an 
MIC ≤ 0.0625 mg/L. The dilution series with ETH only (wells A1 – I1)  showed growth at 
concentrations 64, 32, 16 and 8 mg/L, no growth from 4 mg/L till  1 mg/L and growth again 
at  a concentration of 0.5 mg/L and lower. This indicates an MIC of 1 mg/L. Growth at the 
high concentrations is in keeping with paradoxical susceptibility or Eagle’s phenomenon 
[166]. This was observed in six isolates: TF727, TF1091, TF1400, TF1719, TF2204 and 
TF2226. TF2232 was found to be co-resistant to both INH and ETH, with an MIC of 8 mg/L 
for INH and an MIC ≤ 64 mg/L for ETH.  
This paradoxical effect of ETH was seen with all six isolates that, based on the proposed 
WHO breakpoints (WHO, 4th Edition), had been identified as ETH resisitant while 
susceptible to INH. All the six isolates showed complete susceptibility to INH, where their 
MICs were less than or equal to 0.0625 µg/ml (lowest concentration used). 
35	  
	  
When the growth in wells with the highest concentrations of ETH was subcultured in 7H11 
agar plates, growth with colony morphology compatible with M. tuberculosis was observed 
(Figure 4.2.1.2). Ziehl Neelsen staining confirmed the cultured organims to be acid fast. 
 
 Figure 4.2.2.2: 7H11 agar plates with subcultures from a representative wells of the checkerboard titration.  
A: INH 16mg/L and ETH 64 mg/L 
B: ETH 64 mg/L 
 
To confirm the observed paradoxical susceptibility pattern for ETH with those isolates that 
were selected based on the proposed WHO breakpoints (WHO, 4th Edition) MICs were 
performed with two of the paradoxically susceptible isolates, two M. tuberculosis isolates 
susceptible to INH and ETH, as well as two M. tuberculosis isolates resistant to both INH and 
ETH. The paradoxical effect of both isolates (TF2226 and TF727) was confirmed as shown 





Figure 4.2.2.3: M. tuberculosis isolates tested for ETH susceptibility alone.  
V9124 and TF2284: susceptible to both INH and ETH  
TF2226 and TF727: susceptible to INH; resistant to ETH  
TF2232 and 1291: resistant to INH and ETH. 
 Rows 9 positive control Row 10: negative control  
 
4.3 PCR and DNA Sequencing 
          4.3.1 PCR of ethA, mshA and mshC genes 
No mutations were observed on ethA, mshA and mshC genes. All isolates showing PCR 
product were sequenced, PCR was repeated for those isolates that did not show a PCR 





Figure 4.3.1.1: PCR products of the ethA gene of M. tuberculosis paradoxically susceptible isolates.  
Lanes: 1-TF2204, 2-TF1719, 3-TF1091, 4-TF2226, 5- H37Rv (positive control) and 6-Marker 2. 
 
 
Figure 4.3.1.2: PCR products of the mshA gene of M. tuberculosis paradoxically susceptible isolates.  





Figure 4.3.1.3:  PCR products of the mshC gene of M. tuberculosis paradoxically susceptible isolates.  
Lanes: 1-H37Rv (positive control), 2-TF1400, 3-TF2204, 4-TF1719, 5-TF2226, 6-TF727 and 7-marker 2. 
 
4.3.2 DNA Sequencing 
The sequences of TF727 for ethA, mshC and mshC aligned with a wildtype reference 
sequences (H37Rv) for each of the genes are attached in Annexture 1. The other 6 sequences 
are similar. Annexture 2 contains the chromatograms generated with the DNA sequences. For 
DNA sequence analysis, the generated DNA sequences were examined by alignment with 
reference sequences using Clone Manager 9 Professional Edition software (serial number 
873-081-7617), these were examined in conjunction with the generated chromatograms to 
check if a putative mutation seen from the alignment is a true or false mutation. All 





Chapter 5: Discussion 
Mono-resistance to ethionamide (ETH) in M. tuberculosis is rarely reported. This may be due 
to the fact that ETH resistance is often accompanied with isoniazid (INH) resistance and/or 
resistance to other drugs [99; 139]. Combined resistance to INH and ETH has a molecular 
basis in mutations in inhA. Resistance of M. tuberculosis to ETH is increasing, especially in 
those African countries where use of this drug is part of the standard regimen for treatment of 
multi-drug resistant tuberculosis (MDR-TB) [139]. In this study, we determined the MICs for 
INH and ETH of the selected group of isolates. The selection criteria were susceptibility to 
0.1 mg/L of INH and resistance to 2.5 mg/L of ETH.  Both drugs were tested in combination 
to establish whether inhibiting both related drug targets leads to synergism or antagonism. 
This was done by means of a checkerboard titration. 
The MIC determination as well as the checkerboard titration was done by means of broth 
micro-dilution using a colorimetric growth detection system. The detection methods 
employed were the MTT and the Alamar Blue (MABA) assays . Although the MTT assay has 
shown to give good results with other anti-TB drugs, it was deemed to be unsuitable for our 
study since the reagent reacted with ETH in the absence of bacteria. This may be on the 
account of oxidative activity of EthA. The MABA has also been shown to be an efficient 
method of determining MICs for a number of compounds against mycobacteria [3; 140]. This 
was therefore chosen as an alternative for the MTT assay. In this assay, no interaction with 
the reagent and any of the two drugs was observed. 
Previous studies have shown MICs to be generally lower when tested in liquid media 
compared to MICs tested on solid media [139; 141; 142]. However, there is not much 
information on which of the two media used for drug susceptibility testing best represents 




Combinations of drugs have long been used for the treatment of infections. Such 
combinations provide a broad spectrum of activity, delay or suppress the emergence of drug 
resistance and in some situations allow the use of a decreased dose of individual drugs to 
avoid toxicity [143]. Drug combination regimens are of vital importance in the treatment of a 
number of infections like malaria, HIV infection and TB, where the use of monotherapy has 
been observed to select for resistant mutants [3; 144], ultimately resulting in treatment 
failure. Although combination regimens are the cornerstone of control programmes for 
susceptible as well as drug resistant TB worldwide, studies on the pharmacodynamics of 
these drugs in combination are rare.   
 
In contrast, studies on pharmacokinetic interactions between INH as well as ETH with other 
compounds, including anti-TB drugs, are numerous. INH has been previously reported to 
negatively interact with other compounds [145]. Among the clinically significant interactions 
were those with phenytoin [146 – 150], carbamazepine [151; 152] and certain foods [153 – 
155]. These interactions may result in elevated levels of drug toxicity and insufficient INH 
absorption, if special attention is not given to patients taking INH concomitantly with these 
compounds. INH has been also documented to have pharmacokinetic interactions with other 
anti-tuberculosis drugs such as para-aminosalicylic acid [156] and rifampicin [157], but these 
are not of clinical significance [3].  There also were instances where INH was reported to 
have interactions with antacids [159] anticoagulants [159], benzodiazepines [160] and 
vitamin D [3], which also poses no significant threat to the patient although precautions must 




Absorption of ETH from intestinal tract is almost complete [146], leaving a very small 
proportion of the drug to be excreted in an unchanged form in the stool [161]. Food and 
antacids, unlike in INH absorption, appear to have little effect on the absorption of ETH 
[146] and it has been previously reported that ETH is distributed with ease throughout the 
body [162]. 
 
ETH is given in combination with rifampicin in drug susceptible tuberculous meningitis, 
although the effect of this combination, as well as that of co-administration of ETH with 
other drugs is unknown [161]. Thee and colleagues [161] recently conducted a study of ETH 
serum levels in children given ETH concomitantly with rifampicin over a period of four 
months. This study revealed no significant pharmacokinetic alterations in ETH, although high 
variability was documented in children receiving a South African standard oral dose of 15 – 
20 mg/kg body weight [161]. This was consistent with studies in adults [146; 147; 163]. 
Little is known regarding the accumulation of ETH during continuous therapy in children, but 
no significant clinical interactions between the second-line ETH and first-line drug rifampicin 
were observed [161]. However this does not exclude the possibility of such reactions.  
 
We report on a pharmacodynamic study on the interaction between ETH and INH in vitro. 
We found concentration dependent antagonism between the two drugs in all our INH 
susceptible isolates that showed resistance to 2.5 mg/L of ETH. No such antagonistic effect 
was observed between INH and ETH in the susceptible control strains of M. tuberculosis. 
This suggests that the basis for this phenomenon is not in the composition of the drugs 
themselves, but may be the result of changes in mycolic acid synthesis pathways in our 




Since the standard drug combination of INH, rifampicin, pyrazinamide and ethambutol has 
shown to be highly effective in the treatment of susceptible TB, it is unlikely that any of these 
drugs will have antagonistic effect on the others. However, drug combinations for treatment 
of drug resistant TB are known to be less effective than standard first line treatment. In South 
Africa, the standard treatment regimen for MDR-TB includes ETH but not INH. Therefore, 
our findings do not provide an explanation for the observed poorer response to treatment with 
that regimen as compared to first line treatment. However, the results presented here indicate 
that testing for antagonistic effect between drugs used in combination for treatment of drug 
resistant TB may be useful to improve treatment outcomes. 
 
Henderson and colleagues (2008) proposed a model of ETH metabolism (figure 5.1) [164]. 
ETH is actively metabolized by human FMO2 and mycobacterial EthA to its more reactive 
species, the S-oxide, and the non-reactive 2-etthyl-4-amidopyridine decomposition product. 
Concerns were raised by Palmer et al in 2012, following the outcome of their study, where 
they measured the metabolism and pharmacokinetics of ETH in wild type (WT) mice and 
compared these with the flavin-containing mono-oxygenase deficient knock-out (KO 
fmo1/2/3 null) mice [165]. They found that concentrations of the S-oxide, which is the 
primary metabolite in ETH metabolism, was greater than that of the parent drug in WT mice. 
In KO mice, they observed greater ETH concentrations than S-oxide concentrations. 
Extrapolating their finding to clinical settings, one of their concerns in administering 
clinically relevant doses of ETH to healthy individuals with normal flavin mono-oxygenase 
activity (represented by the WT mice), would be chronic oxidative stress due to the S-oxide 
mediated depletion of glutathione (figure 5.1). On the other hand, accumulation of ETH over 
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multiple doses in individuals with the FMO2*2 genotype (represented by the KO mice) was 
thought to be clinically more relevant. The authors suggest that interactions of ETH with co-
administered drugs through competitive inhibition may occur [166]. Such competitive 
inhibition could aggravate the observed antagonistic effect of ETH on INH in patients. This 
needs further investigation.  
 
Figure 5.1: Representation of oxidative stress and toxicity in ETH metabolism pathway 
[165]. 
 
Our study revealed a paradoxical effect of ETH on our selected isolates, where growth was 
observed at high concentrations of ETH but not with lower concentrations. Growth 
reappeared at drug concentrations below the MIC of the isolate. The growth intensity, as 
depicted by the colour signal, decreased with decreasing ETH concentrations. This 
phenomenon was first described by Harry Eagle in 1948, where he observed a decreased 
activity of penicillin against strains of certain bacterial species at high concentrations [166]. 
Eagle argued the previous hypothesis posed by Garrod (1945) who reported similar 
observations. Garrod attributed this retarded activity of penicillin to impurities in the drug 
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[167]. Eagle found this interpretation inconsistent with his findings and described this zonal 
inhibition as a ‘paradoxical effect’ of penicillin. Until a decade ago, such reactions have not 
been reported in in vitro susceptibility testing of anti-tuberculosis drugs. A study by Abate 
and colleagues in 2002 showed thiacetazone to have a paradoxical effect on certain strains of 
M. tuberculosis. They observed this drug to have greater inhibiting activity at lower 
concentrations as opposed to higher concentrations [168]. Thiacetazone is not used in South 
Africa in first line treatment of TB, however it may still be considered for the control of drug 
resistant TB [168]. 
 
The paradoxical effect of ETH and antagonism between ETH and INH was confirmed by the 
presence of growth on Middlebrook 7H11 plates, following sub-culturing of our isolates from 
the wells with the highest concentrations of ETH alone and in combination with INH, at the 
highest concentrations. This eliminates the possibility that a reaction between ETH and 
alamar blue is the cause of the observed colour change. It can be concluded that both the 
paradoxical effect of ETH and the antagonistic reaction between ETH and INH in our isolates 
does not result from mutations found in ethA, mshA or mshC genes, which are commonly 
implicated in high level resistance of isolates of M. tuberculosis to ETH [41; 169]. Further 
investigations have to be done to elucidate the mechanism by which both these phenomena 
occur in our isolates.  
 
The proposed WHO resistance breakpoint for ETH in liquid media is 2.5 to 5 mg/L and on 
solid agar media 5 to 10 mg/L. We selected isolates that showed mono-resistance to ETH 
using these breakpoints. However, this resulted in a wrong selection since the true MIC in of 
these isolates in liquid media was shown to be 1 mg/L. Therefore these isolates are fully 
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susceptible which is corroborated by the absence of mutations in the msh genes and ethA. 
This error is based on the paradoxical phenomenon. To avoid false reporting of ETH 
resistance, tests using lower concentrations need to be included. Whether this paradoxical 
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Preparation of probe DNA by PCR [170]: 
Preparation of PCR mix. Required per reaction; 
10x PCR buffer (Saiki)                             5µl 
dNTP mix (each dNTP; 2.5 mM)             4µl 
Primer 1 (50 ng/µl)                                   5µl 
Primer 2 (50 ng/µl)                                   5µl 
Primers: 
INS-1  5’ CGTGAGGGCATCGAGGTGGC 3’ 
INS-2  5’ GCGTAGGCGTCGGTGACAAA  3’ 
To the PCR mix, 0.25 µl Taq polymerase (1.25 U) (Ampli-Taq) per reaction was added. The 
mix was vortexed and kept on ice. PCR mix was transferred to PCR tube in 20 ml aliquots. 
30µl of the target DNA preparation (10 ng) isolated from M. bovis BCG was added to the 
PCR mix. The reaction mixture was overlayed with approximately 75 µl mineral oil (paraffin, 
Sigma), to prevent evaporation. This was mixed and centrifuged for 5 seconds in a 
microcentrifuge at 12 000 g. Program used for denaturing-annealing-synthesizing cycle: 
3 min 94⁰C       once 
1 min 94⁰C      25 cycles 
1 min 65⁰C      25 cycles 
2 min 72⁰C       25 cycles 
4 min 72⁰C      once  
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The PCR products were examined by electrophoresis and staining with ethidium bromide. 
The PCR fragments should be 245 bp in length using primers INS-1 and INS-2 from IS6110. 
When the correctly sized fragments were obtained, purification on a Sephadex column was 
used. The PCR products were carefully collected by carefully pipetting the samples from 
under the oil in fresh microcentrifuge tubes. If necessary, the collected samples were 
centrifuged at 12000 g to be able to move the rest of the oil. A Quick SpinTM Sephadex G-50 
column (Boehringer Mannheim) was removed from its zip-lock bag and was gently inverted 
several times to re-suspend the medium. The top cap was removed from the column, then the 
bottom tip was removed. This sequence is necessary to avoid creating a vacuum and uneven 
flow of the buffer. The buffer was allowed to drain and was discarded. The column was 
placed in a collection tube (10 ml) and was centrifuged at 200g in a swing out rotor for 2 
minutes. The collection tube was discarded with the eluted buffer. 100 µl of the sample was 
applied to the censer of the column bed. The column was placed in an upright position in 
fresh collection tube and was centrifuged for 4 minutes at 200 g in a swing out rotor. The 
eluate from the second collection tube contained the purified DNA. 100 µl of 1XTE and 
500µl 96% ethanol was added to precipitate the DNA. This was stored at -20⁰C for 30 
minutes. This was spun in a microcentrifuge for 15 minutes at room temperature at 12000g. 
The supernatant was discarded leaving the last 20 µl above the pellet. 1ml of 70% ethanol 
was added and the tube was carefully shaken. This was spun for 5 minutes in a 
microcentrifuge at room temperature and the supernatant was discarded leaving the last 20 µl 
above the pellet. This was again spun for 1 minute and the last 20 µl of ethanol was removed 
using a pipette and the pellet was permitted to air dry at room temperature for 10 minutes. 
The pellet was dissolved in 50 µl of 0.1XTE. The concentration of the PCR fragment was 



















Buffers and solutions 
10X TBE:  
108g Tris base  
55g boric acid  
9.3g EDTA  
Add distilled water up to 1000ml 
 
20X SSC:  
173g NaCl  
88.2g sodium citrate  
Add distilled water up to 1000ml, pH=7  
 
Soak I:  
20g NaOH (0.5M)  
87.66g NaCl (1.5M)  






Soak II:  
62.6g Tris base (0.5M)  
87.6g NaCl (1.5M)  
40ml HCl  
Add distilled water up to 1000ml, pH=7.2 
 
Hybridization buffer (500ml):  
29.22g NaCl (0.3M)  
20g blocking agent  
 
10x PCR buffer:  
30Mm MgCl2   
100Mm Tris-HCl pH 8.3  
500Mm KCL  
0.2 gelatine 
 
Primary wash buffer:  
360g urea  
4g SDS (or 20ml of 20% SDS)  
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25ml 20X SSC  
Add distilled water up to 1000ml 
 
Secondary wash buffer:  
2X SSC 
 
Gel loading buffer:  
5ml 10X TBE  
25ml glycerol (Merck, Germany)  
15ml distilled water  
5ml 1% DD 
 
1% DD:  
1g bromophenol blue  
1g xylene cyanole  
100ml distilled water 
  
 
	  
